Two out of the three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 49 points (0.3%) at 16,534 as of Thursday, Feb. 25, 2016, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,585 issues advancing vs. 1,317 declining with 152 unchanged.

The Drugs industry currently sits down 0.6% versus the S&P 500, which is up 0.1%. Top gainers within the industry include

Sanofi

(

SNY

), up 2.1%,

GlaxoSmithKline

(

GSK

), up 1.5%,

Novo Nordisk A/S

(

NVO

), up 1.4%,

AstraZeneca

(

AZN

), up 1.2% and

Teva Pharmaceutical Industries

(

TEVA

), up 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

AbbVie

(

ABBV

) is one of the companies pushing the Drugs industry higher today. As of noon trading, AbbVie is up $0.41 (0.8%) to $55.30 on light volume. Thus far, 2.3 million shares of AbbVie exchanged hands as compared to its average daily volume of 9.4 million shares. The stock has ranged in price between $54.43-$55.80 after having opened the day at $55.17 as compared to the previous trading day's close of $54.89.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $88.7 billion and is part of the health care sector. Shares are down 7.3% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts who rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

AbbVie

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

AbbVie Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Allergan

(

AGN

) is up $6.27 (2.2%) to $290.97 on average volume. Thus far, 1.2 million shares of Allergan exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $285.03-$292.32 after having opened the day at $285.42 as compared to the previous trading day's close of $284.70.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, generic, branded generic, biosimilar, and over-the-counter pharmaceutical products worldwide. Allergan has a market cap of $113.0 billion and is part of the health care sector. Shares are down 8.9% year-to-date as of the close of trading on Wednesday. Currently there are 11 analysts who rate Allergan a buy, 1 analyst rates it a sell, and none rate it a hold.

TheStreet Ratings rates

Allergan

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. However, as a counter to these strengths, we find that the stock has had a decline in price during the past year. Get the full

Allergan Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Pfizer

(

PFE

) is up $0.46 (1.5%) to $30.48 on average volume. Thus far, 18.8 million shares of Pfizer exchanged hands as compared to its average daily volume of 37.5 million shares. The stock has ranged in price between $30.02-$30.53 after having opened the day at $30.10 as compared to the previous trading day's close of $30.02.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Pfizer has a market cap of $184.9 billion and is part of the health care sector. Shares are down 7.0% year-to-date as of the close of trading on Wednesday. Currently there are 7 analysts who rate Pfizer a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Pfizer

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Pfizer Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).